In summary, our study represents the first to investigate the differences in the frequency of GNAS and KRAS mutations between two distinct IPMN cohorts—one undergoing conservative monitoring and the other with recommendations for surgical intervention. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.